These results suggest that dysfunction of the regulatory mechanisms governing ERα genomic binding contribute to the development of endocrine‐resistant ER+ breast cancer, and we hypothesized that chromatin remodeling enzymes that can regulate the ERα genomic landscape may contribute to endocrine resistance. Here, ESR1 is linked to breast carcinoma.